For the Six Months Ended
June 30, July 1,
2007 2006
Cash flow from operating activities:
Loss from continuing operations $ (15,992) $ (29,119)
Adjustments to reconcile loss
from continuing operations to net
cash used in operating activities
from continuing operations:
Depreciation and amortization 4,150 4,464
Provision for slow moving or
obsolete inventory 111 453
Non-cash compensation 1,515 1,789
Gain on sale of assets, net (2,557) -
Disposal of fixed assets, net 40 236
Other 96 (407)
Changes in assets and liabilities:
Trade accounts receivable 3,875 4,277
Inventories (85) (2,097)
Prepaid expenses and other
current assets (634) (100)
Other assets 15 80
Accounts payable and accrued
expenses (3,589) (7,257)
Total adjustments 2,937 1,438
Net cash used in operating activities
from continuing operations (13,055) (27,681)
Net cash used in operating activities
from discontinued operations (5,803) (5,990)
Net cash used in operating activities (18,858) (33,671)
Cash flow from investing activities:
Purchases
'/>"/>
SOURCE Nabi Biopharmaceuticals
 Copyright©2007 PR Newswire. | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 Related medicine technology :1.
Inspiration Biopharmaceuticals Presents Data From Hemophilia
Program at International Society On Thrombosis and Haemostasis
(ISTH) Annual Meeting2.
Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase
II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple
Myeloma and Waldenstroms Macroglobulinemia3.
Accentia Biopharmaceuticals Announces Favorable Interim Blinded
Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial
for Chronic Sinusitis4.
Keryx Biopharmaceuticals, Inc. Announces Poster Presentations
Highlighting Mechanism of Action and Clinical Activity of
Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American
Diabetes Association 67th Scientific Sessions in Chicago, Illinois5.
Accentia Biopharmaceuticals Scientific Presentations Demonstrate
Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at
the Annual Meeting of the American Academy of Allergy, Asthma, and
Immunology6.
Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial7.
Sygnis Pharma AG announces date for presentation of clinical
results8.
Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis9.
Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy
of BF-200 ALA In Actinic Keratosis10.
YM BioSciences Announces Secondary Efficacy and Safety Findings in
Randomized Phase IIB Aerolef Trial11.
BioSante Pharmaceuticals Announces New Findings for Potential Bird
Flu Vaccine